Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Berlin

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Oncology (Williston Park, N.Y.)|November 13, 2001
Chemotherapy for resectable and advanced pancreatic cancerJ D Berlin, M Rothenberg
Cell and Tissue Research|January 12, 1977
Cytoplasmic annulate lamellae in human spermatogenesisF E Smith, J D Berlin
Cell and Tissue Research|February 27, 1976
The fine structural localization of testicular phosphatases in man: the control testisS S Barham, J D Berlin, R B Brackeen
American Industrial Hygiene Association Journal|August 1, 1980
Capitate hairs on cotton textile wastesK Kosmidou-Dimitropoulou, P R Morey, J D Berlin
Cancer|December 1, 1976
Morphologic and immunologic studies of a human colon tumor cell line (SW-48)W B McCombs, A Leibrovitz, C E McCoy, et al.
Pharmacotherapy|December 22, 1999
Warfarin-5-FU interaction--a consecutive case seriesJ M Kolesar, C L Johnson, B L Freeberg, et al.
Oncology|April 15, 2000
A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296)J D Berlin, S Adak, D J Vaughn, et al.
American Journal of Clinical Oncology|April 16, 1998
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889)J D Berlin, K J Propert, D Trump, et al.
Investigational New Drugs|July 30, 1999
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumorsJ D Berlin, D B Alberti, R Z Arzoomanian, et al.
ESMO Open|April 19, 2024
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutationsJ Rodon, E Rodriguez, M L Maitland, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Oncology (Williston Park, N.Y.)|November 13, 2001
Chemotherapy for resectable and advanced pancreatic cancerJ D Berlin, M Rothenberg
Cell and Tissue Research|January 12, 1977
Cytoplasmic annulate lamellae in human spermatogenesisF E Smith, J D Berlin
Cell and Tissue Research|February 27, 1976
The fine structural localization of testicular phosphatases in man: the control testisS S Barham, J D Berlin, R B Brackeen
American Industrial Hygiene Association Journal|August 1, 1980
Capitate hairs on cotton textile wastesK Kosmidou-Dimitropoulou, P R Morey, J D Berlin
Cancer|December 1, 1976
Morphologic and immunologic studies of a human colon tumor cell line (SW-48)W B McCombs, A Leibrovitz, C E McCoy, et al.
Pharmacotherapy|December 22, 1999
Warfarin-5-FU interaction--a consecutive case seriesJ M Kolesar, C L Johnson, B L Freeberg, et al.
Oncology|April 15, 2000
A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296)J D Berlin, S Adak, D J Vaughn, et al.
American Journal of Clinical Oncology|April 16, 1998
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889)J D Berlin, K J Propert, D Trump, et al.
Investigational New Drugs|July 30, 1999
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumorsJ D Berlin, D B Alberti, R Z Arzoomanian, et al.
ESMO Open|April 19, 2024
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutationsJ Rodon, E Rodriguez, M L Maitland, et al.
Pageof 2